Optimization of forced degradation using Experimental design and development of a stability-indicating liquid chromatographic assay method for rebamipide in bulk and tablet dosage form

Scientia Pharmaceutica

Volumn 79, Issue 1, 2011, Pages 85-96

  Sonawane, Sandeep ^a   Gide, Paraag ^a  

^a MET's Institute of Pharmacy   (India)

Author keywords

Degradation product; Experimental design; Microwave energy; Rebamipide; RP HPLC; Stability indicating; Validation

Indexed keywords

HYDROGEN PEROXIDE; REBAMIPIDE;

ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM; HYDROLYSIS; LIQUID CHROMATOGRAPHY; OXIDATION; PHOTODEGRADATION; TABLET; TEMPERATURE STRESS; VALIDATION PROCESS;

EID: 79952958633     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1011-06     Document Type: Article

References (17)

1. Klick S, Muijselaar P, Eichinger T, Korn C, Gerding T, Debert A, Griend C, Beld C, Somsen G, Jong G. Towards generic approach for stress testing of drug substances and drug products. Phrm Technol Online. 2005; 48-66.
2. International Conference of Harmonization. Stability Testing of New Drug Substances and Products, Q1A (R2). International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. IFPMA, 2003, Geneva.
3. Singh S, Bakshi M. Guidance on Conduct of Stress tests to determine inherent stability of drugs. Pharm Technol Online. 2000; 1-24.
4. Singh S, Bakshi M. Development of validated stability-indicating assay methods-critical review. J Pharm Biomed Anal. 2002; 28: 1011-1040. doi:10.1016/S0731-7085(02)00047-X
5. Dolan JW. Stability-indicating assay. LCGC North America. 2002; 20: 347-349.
6. Lundstedt T, Seifert E, Abramo L, Thelin B, Nystrom A, Pettersen J, Bergamn R. Experimental Design and optimization. Chemom Intell Lab Syst. 1998; 42: 3-40. doi:10.1016/S0169-7439(98)00065-3
7. Bolton S, Bon C. Pharmaceutical Statistics Practical and Clinical Application. In: Optimization techniques and screening designs. 4th ed. Marcel Dekker, Inc; 2004: 506-523.
8. Mavandadi F, Pilotti A. The Impact of Microwave-assisted Organic Synthesis in Drug Discovery. Drug Discov Today. 2006; 11: 165-174. doi:10.1016/S1359-6446(05)03695-0
9. The Merk Index. Merck and Co., Inc., 2001; Whitehouse Station, NJ: 1456.
10. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki K, Oshitani Y, Yoshikawa T, Tarnawski A. 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications. Dig Dis Sci. 2005; 50 (Suppl 1): S5-S11. doi:10.1007/s10620-005-2800-9
11. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet's Disease: A Randomised, Double-Blind, Placebo-Controlled Study. Drugs R & D. 2003; 4: 19-28. doi:10.2165/00126839-200304010-00002
12. Shioya Y, Shimizu T. High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3-[2(1H)-quinlinon-4-yl]propionic acid, in human plasma and urine. J Chromatogr B Biomed Sci App. 1988; 434: 283-287. doi:10.1016/0378-4347(88)80089-6
13. Jeoung M, Kim C, Kim N, Hong J, Chung Y, Park Y, Kim K, Moon D. Determination of Rebamipide in Human Plasma by HPLC. J Liq Chromatogr Relat Technol. 2004; 27: 1925-1935. dio:10.1081/JLC-120038778
14. Son D, Thuong N, Park E, Chi S. High Performance Liquid Chromatographic Analysis of Rebamipide in Human Plasma. Anal Lett. 2005; 38: 997-1005. doi:10.1081/AL-200054071
15. Manglani UR, Khan I, Soni K, Loya P. Development and Validation of HPLC-UV method for estimation of Rebamipide in Human Plasma. Indian J Pharm Sci. 2006; 68: 475-478. doi:10.4103/0250-474X.27821
16. International Conference of Harmonization. Validation of Analytical Procedures: Text and Methodology, Q1A (R1). International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. IFPMA, 2005, Geneva.
17. nd edition, A Wiley-Interscience Publication, John Willy & Sons Inc,. 735-739.